The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.
Open accessAbstract
Androgens promote the growth and differentiation of prostate cells through ligand activation of the androgen receptor (AR). Sensitization of the androgenic response by multifunctional growth factor signaling pathways is one of the mechanisms via which AR contributes to the emergence of androgen-independent prostate tumors. The ability of AR to cross-talk with key growth factor signaling events toward the regulation of cell cycle, apoptosis, and differentiation outcomes in prostate cancer cells is established. In this paper, we review the functional interaction between AR and an array of growth factor signal transduction events (including epidermal growth factor; fibroblast growth factor; IGF1; vascular endothelial growth factor; transforming growth factor-beta) in prostate tumors. The significance of this derailed cross-talk between androgens and key signaling networks in prostate cancer progression and its value as a therapeutic forum targeting androgen-independent metastatic prostate cancer is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The expression of EGF and its receptor (EGFR) are increased in patients with advanced, aggressive prostate cancer, and both molecules have been implicated in the development and progression of many other kinds of tumors (33).”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [33]
In the citing paper
“The ability of mitogenic growth factors such as EGF and IGF to stimulate intracellular signaling that cross talks with those of the AR has been extensively reviewed elsewhere (33).”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,498
Lipid rafts and signal transduction
Simons, K., & Toomre, D. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35036052 · Cited by 5,371
JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
Hoskins, R. G. (1953) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-13-4-473 · Cited by 3,780
Roberts, A. B., Sporn, M. B., Assoian, R. K., Smith, J. M., Roche, N. S., Wakefield, L. M., Heine, U., Liotta, L. A., Falanga, V., & Kehrl, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4167 · Cited by 2,867
Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
Fong, G.-H., Rossant, J., Gertsenstein, M., & Breitman, M. L. (1995) · Nature · doi:10.1038/376066a0 · Cited by 2,606
Molecular and cellular endocrinology
(1995) · Journal of Endocrinology · doi:10.1677/joe.0.147so19 · Cited by 1,986
Ornitz, D. M., & Itoh, N. (2001) · Genome biology · doi:10.1186/gb-2001-2-3-reviews3005 · Cited by 1,985
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
TGF-β and epithelial-to-mesenchymal transitions
Zavadil, J., & Böttinger, E. P. (2005) · Oncogene · doi:10.1038/sj.onc.1208927 · Cited by 1,628
Craft, N., Shostak, Y., Carey, M., & Sawyers, C. L. (1999) · Nature Medicine · doi:10.1038/6495 · Cited by 980
Cited by
Sorted by citations
Androgen receptor signaling in prostate cancer development and progression
Tindall, D. J., & Lonergan, P. E. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.83937 · Cited by 544
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Shafi, A. A., Yen, A. E., & Weigel, N. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.003 · Cited by 435
Menden, M. P., Wang, D. Y. Q., Mason, M. J., Szalai, B., Bulusu, K. C., Guan, Y., Yu, T. V., Kang, J., Jeon, M., Wolfinger, R. D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09799-2 · Cited by 371
Inflammation and prostate cancer: the role of interleukin 6 ( IL ‐6)
Nguyen, D. P., Li, J., & Tewari, A. K. (2013) · British Journal of Urology · doi:10.1111/bju.12452 · Cited by 357
Drug resistance in metastatic castration-resistant prostate cancer
Šeruga, B., Ocaña, A., & Tannock, I. F. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.136 · Cited by 346
Metadata
- Authors
- Zhu, M.-L., & Kyprianou, N.
- Affiliations
- University of Kentucky HealthCare (US)
- Venue
- Endocrine Related Cancer
- Publisher
- Bioscientifica
- Published
- 2008-09-10
- Volume
- 15
- Issue
- 4
- Pages
- 841-849
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- PMC
- PMC2740735
- OpenAlex
- W2167609397
- Cited by
- 286
- References
- 105
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 12 · 2023: 16 · 2022: 12 · 2021: 16 · 2020: 9 · 2019: 15 · 2018: 13 · 2017: 17 · 2016: 18 · 2015: 23 · 2014: 10 · 2013: 29 · 2012: 17
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Related Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK-53525-08, R01DK053525)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Reproductive Medicine › Sperm and Testicular Function
- Keywords
- androgen receptor, growth factor signaling, signaling crosstalk, prostate cancer, castration-resistant prostate cancer, metastatic prostate cancer, epidermal growth factor, fibroblast growth factor, insulin-like growth factor I, vascular endothelial growth factor, TGF-beta, cell cycle regulation, apoptosis, therapeutic target
- MeSH terms
- Animals, Humans, Male, Prostatic Neoplasms, Receptors, Androgen, Signal Transduction, Gene Expression Regulation, Neoplastic, Receptor Cross-Talk, Intercellular Signaling Peptides and Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
